Hennion & Walsh Asset Management, Inc. Altimmune, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 129,276 shares of ALT stock, worth $801,511. This represents 0.05% of its overall portfolio holdings.
Number of Shares
129,276Holding current value
$801,511% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding ALT
# of Institutions
191Shares Held
42.4MCall Options Held
1.05MPut Options Held
582K-
Black Rock Inc. New York, NY5.32MShares$33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.91MShares$30.4 Million0.0% of portfolio
-
State Street Corp Boston, MA3.91MShares$24.2 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.22MShares$20 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$17.1 Million2.23% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $304M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...